tiprankstipranks
Advertisement
Advertisement

Rigel Pharmaceuticals Appoints Michael P. Miller to Board

Story Highlights
  • On February 1, 2026, Rigel appointed Michael P. Miller to its board and Compensation Committee.
  • Miller will receive standard cash and equity director compensation, with the board confirming his independence and lack of conflicts.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Rigel Pharmaceuticals Appoints Michael P. Miller to Board

Claim 30% Off TipRanks

Rigel ( (RIGL) ) has issued an update.

On February 1, 2026, Rigel Pharmaceuticals appointed Michael P. Miller to its board of directors, where he will serve in the director class whose term runs until the 2027 annual stockholders’ meeting and take a seat on the company’s Compensation Committee. Miller will receive Rigel’s standard non-employee director compensation package, including prorated annual cash retainers for board and committee service, an initial option grant to purchase 12,000 shares under the company’s equity incentive plan, and future annual equity awards, along with standard indemnification; the board has deemed him independent, with no related-party, familial, or special appointment arrangements disclosed, underscoring Rigel’s adherence to governance and compliance norms for board composition.

The most recent analyst rating on (RIGL) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.

Spark’s Take on RIGL Stock

According to Spark, TipRanks’ AI Analyst, RIGL is a Outperform.

Overall score is driven primarily by strong financial performance (high margins and solid cash conversion) and attractive valuation (low P/E). Technicals support the thesis with an established uptrend and neutral-to-positive momentum, while the latest earnings call and subsequent events reinforce growth via raised guidance, strong preliminary results, and encouraging pipeline progress, partially offset by the CNS program termination risk.

To see Spark’s full report on RIGL stock, click here.

More about Rigel

Rigel Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small-molecule drugs, with its operations centered on discovering therapies for unmet medical needs in specialized disease areas.

Average Trading Volume: 588,799

Technical Sentiment Signal: Buy

Current Market Cap: $632.8M

For an in-depth examination of RIGL stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1